Health & Fitness
Thu, September 22, 2011Wed, September 21, 2011Tue, September 20, 2011Mon, September 19, 2011Sun, September 18, 2011Sat, September 17, 2011Fri, September 16, 2011Thu, September 15, 2011Wed, September 14, 2011Tue, September 13, 2011Mon, September 12, 2011Sun, September 11, 2011Sat, September 10, 2011Fri, September 9, 2011Thu, September 8, 2011Wed, September 7, 2011Tue, September 6, 2011Mon, September 5, 2011Sun, September 4, 2011Sat, September 3, 2011Fri, September 2, 2011Thu, September 1, 2011Wed, August 31, 2011Tue, August 30, 2011Mon, August 29, 2011Fri, August 26, 2011Thu, August 25, 2011Wed, August 24, 2011Tue, August 23, 2011Array BioPharma Names Karsten Witt,;; M.D.,;; Vice President of Clinical Sciences
Published in Health and Fitness on Thursday, September 8th 2011 at 21:01 GMT by Market Wire
BOULDER, Colo.--([ BUSINESS WIRE ])--Array BioPharma Inc. (NASDAQ: ARRY) today announced that Karsten Witt, M.D., has joined the Company as Vice President of Clinical Sciences. With 26 years of experience in the field of medicine and 19 years working in the pharmaceutical industry, Dr. Witt will lead clinical science and drug safety activities for Arraya™s pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.
"Karsten brings valuable experience to Array to help us move our proprietary pipeline to the next level"
aKarsten brings valuable experience to Array to help us move our proprietary pipeline to the next level," said Robert E. Conway, Chief Executive Officer. "His expertise in advancing therapeutics for cancer and inflammation, including the registration of Tarceva® (erlotinib), will enable him to make immediate contributions to our proprietary programs as we move into pivotal studies. I am excited to have Karsten on the Array team.a
Dr. Witt has been involved in filing six investigational new drug applications and five new drug applications across the U.S., Europe and Japan, including the registration of Tarceva® (erlotinib). From 2002 until he joined Array, Dr. Witt served as Sr. Vice President Pharmaceutical Operations at OSI Pharmaceuticals, where he was intimately involved in the development of small-molecule targeted oncology therapies, including the EGFR inhibitor Tarceva®. Dr. Witt also served as a member of OSIa™s Executive Management Committee starting in 2008. From 1998 to 2001, Dr. Witt was Sr. Director of Clinical Research & Drug Safety at NeXstar Pharmaceuticals, and continued in that position after NeXstara™s acquisition by Gilead Sciences Inc. Dr. Witt worked at Synergen, where he assisted in setting up the companya™s European Headquarters; in 1995, after Amgen purchased Synergen, he continued as a Clinical Scientist, working primarily on inflammation programs, including the IL-1ra program which subsequently produced Kineret®(anakinra). Dr. Witt received his medical degree in 1985 from the University of Copenhagen in Denmark and practiced medicine for six years at a university hospital in Copenhagen.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to [ www.arraybiopharma.com ].
